# Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis

> **NCT03983252** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Brigham and Women's Hospital**

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** [F-18]PBR06

## Key facts

- **NCT ID:** NCT03983252
- **Lead sponsor:** Brigham and Women's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12
- **Primary completion:** 2024-05-01
- **Final completion:** 2024-05-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The study was terminated without recruitment.
- **Last updated:** 2025-10-20

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03983252

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03983252, "Effect of Alemtuzumab on Microglial Activation Positron Emission Tomography (PET) in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03983252. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*